AMLX

AmylyxD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$24.00

+80.6% vs current

Most likely

Base case

45%

Probability

Target price

$17.00

+27.9% vs current

B-

Bear case

30%

Probability

Target price

$9.50

-28.5% vs current

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

Primary-source evidence is solid, but the current setup still looks like a cautious monitoring story rather than a broad fundamental inflection: recent headlines are pipeline-progress oriented, not revenue-driven, deterministic priors are negative across 5d to 120d, and there is no strong secondary evidence here of broad post-filing estimate upgrades or expanding coverage. Headline buzz is moderate because of the March enrollment update, but conviction should stay restrained until the Q3 2026 avexitide readout clarifies whether the main catalyst is value-creating or value-destructive.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30eventAvexitide Phase 3 LUCIDITY topline data in Q3 2026High impact

Management's March 2026 materials say Phase 3 LUCIDITY enrollment is complete, topline avexitide data are expected in Q3 2026, and a successful readout would be the clearest near-term re-rating driver for AMLX [#8-K-2026-03-24] [#10-K-2026-03-03].

2026-12-31catalystAdditional pipeline execution updates beyond avexitideHigh impact

Amylyx's March 2026 8-K presentation also highlighted completed enrollment for Cohort 2 of the Phase 1 LUMINA trial and said AMX0035 in Wolfram syndrome is pending FDA alignment for a focused pivotal Phase 3 plan, giving the stock secondary execution checkpoints even before the main Phase 3 avexitide readout [#8-K-2026-03-24].

2028-01-01catalystCash runway supports pipeline into 2028High impact

The 10-K states AMLX had $317.0 million of cash, cash equivalents and marketable securities at December 31, 2025 and believes that cash funds operations into 2028, which lowers near-term financing pressure while multiple clinical programs mature [#10-K-2026-03-03].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology